OSE Immunotherapeutics Stock OTC Markets
Stocks
ORPHF
FR0012127173
Biotechnology & Medical Research
OTC Markets Traded
| Market Cap | 91.49M 106M 84.31M 78.92M 148M 10.07B 150M 996M 388M 4.9B 398M 389M 16.97B | P/E Ratio 2026 * |
-3x | P/E Ratio 2027 * | -3.44x |
|---|---|---|---|---|---|
| Enterprise Value | 131M 152M 121M 113M 212M 14.46B 216M 1.43B 557M 7.04B 571M 559M 24.37B | EV / Sales 2026 * |
21x | EV / Sales 2027 * | 14.6x |
| Free-Float |
74.23% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: OSE Immunotherapeutics
| 1 day | +190.00% |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Bozec
CEO | Chief Executive Officer | - | 2025-10-01 |
Thomas Gidoin
DFI | Director of Finance/CFO | 43 | 2025-08-19 |
Silvia Comis
CTO | Chief Tech/Sci/R&D Officer | - | 2021-12-19 |
| Director | Title | Age | Since |
|---|---|---|---|
Maryvonne Hiance
BRD | Director/Board Member | 77 | 2016-05-30 |
Brigitte Dreno
BRD | Director/Board Member | 73 | 2017-06-13 |
| Director/Board Member | - | 2023-06-21 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +190.00% | +143.99% | - | - | 106M | |
| -0.35% | +0.97% | -13.80% | -13.25% | 43.03B | |
| +3.11% | +3.11% | +279.08% | +501.52% | 32.71B | |
| +0.22% | -1.08% | +15.66% | -15.65% | 30.29B | |
| +1.62% | -2.08% | -1.91% | +24.64% | 29.4B | |
| +4.09% | +0.93% | +12.97% | +20.22% | 25.08B | |
| +1.14% | +3.62% | - | - | 13.54B | |
| -1.63% | +2.88% | +56.69% | +113.41% | 13.35B | |
| -0.40% | -1.29% | +6.23% | +7.63% | 12.97B | |
| -0.74% | -1.62% | +105.89% | +74.92% | 12.11B | |
| Average | +19.71% | +1.65% | +57.60% | +89.18% | 23.61B | |
| Weighted average by Cap. | +1.14% | +1.63% | +57.30% | +96.08% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 6.25M 7.24M 5.76M 5.39M 10.1M 688M 10.26M 68.01M 26.51M 335M 27.16M 26.58M 1.16B | 10.53M 12.19M 9.7M 9.08M 17.02M 1.16B 17.29M 115M 44.67M 564M 45.76M 44.78M 1.95B |
| Net income | -30.59M -35.41M -28.19M -26.38M -49.44M -3.37B -50.21M -333M -130M -1.64B -133M -130M -5.67B | -21.47M -24.85M -19.78M -18.52M -34.7M -2.36B -35.24M -234M -91.07M -1.15B -93.28M -91.29M -3.98B |
| Net Debt | 39.88M 46.18M 36.75M 34.4M 64.47M 4.39B 65.47M 434M 169M 2.14B 173M 170M 7.4B | 62.23M 72.05M 57.35M 53.68M 101M 6.85B 102M 677M 264M 3.33B 270M 265M 11.54B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
